Lifordi Immunotherapeutics

Lifordi is conducting a Phase 1 clinical trial of LFD-200 for rheumatoid arthritis, assessing safety, efficacy, and biologic effects.

LFD-200 combines antibody-drug conjugates with glucocorticoids to create a new therapeutic approach for autoimmune and inflammatory diseases.

Arthur O. Tzianabos, Ph.D., leads Lifordi Immunotherapeutics as President and CEO and serves as a Venture Partner at 5AM Ventures. He has over 30 years of experience in biotechnology and academia, focusing on discovery, development, clinical translation, and commercialization of immunology and rare disease treatments.

Dave Nichols has over 25 years of experience in process development, GMP clinical and commercial manufacturing, and quality control for biologics, including antibody drug conjugates and small molecules.

Dr. McClure has over 20 years of knowledge and hands-on experience in all phases of clinical development and global operations across a broad range of therapeutic areas spanning from orphan diseases to highly prevalent diseases. Following his medical training at Duke University, he worked at biotechnology companies in roles of increasing responsibility, including as Chief […]

Naina Bhasin, Ph.D. brings to Lifordi 20 years of life science experience in corporate and business development, strategic planning, and operations. Dr. Bhasin’s broad understanding of the needs of emerging companies has led to a successful track record in building teams, functions, and organizations. Most recently, Dr. Bhasin served as Chief Business Officer at Ensoma […]

Lifordi develops antibody-drug conjugates (ADCs) for autoimmune and inflammatory disorders, with its first program, LFD-200, in a Phase 1 clinical study for rheumatoid arthritis.

Lifordi is among the first companies to leverage the success of antibody-drug conjugates (ADC) to develop treatments for autoimmune and inflammatory disorders.